Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer.

ABSTRACT: Chromodomain-helicase-DNA-binding protein 4 (CHD4) is an epigenetic regulator identified as an oncogenic element that may provide a novel therapeutic target for the treatment of breast cancer (BC). CHD4-the core component of the nucleosome remodeling and deacetylase (NuRD) complex-may be mutated in patients with this disease. However, information on CHD4 mutants that might allow their use as biomarkers of therapeutic success and prognosis is lacking. The present work examines mutations in CHD4 reported in patients with breast cancer and included in public databases and attempts to identify their roles in its development. The databases revealed 81 point mutations across different types of breast cancer (19 of which also appeared in endometrial, intestinal, nervous system, kidn

SUBMITTER: Novillo A 

PROVIDER: S-EPMC8107472 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature